Immunocompromised Clinical Trials

9 recruitingLast updated: May 21, 2026

There are 9 actively recruiting immunocompromised clinical trials across 10 countries. Studies span Phase 2, Phase 1, Phase 3. Top locations include Pavia, Pavia, Italy, Houston, Texas, United States, Cincinnati, Ohio, United States. Updated daily from ClinicalTrials.gov.


Immunocompromised Trials at a Glance

9 actively recruiting trials for immunocompromised are listed on ClinicalTrialsFinder across 6 cities in 10 countries. The largest study group is Phase 2 with 2 trials, with the heaviest enrollment activity in Pavia, Houston, and Cincinnati. Lead sponsors running immunocompromised studies include Fondazione IRCCS Policlinico San Matteo di Pavia, Children's Hospital Medical Center, Cincinnati, and Assistance Publique - Hôpitaux de Paris.

Browse immunocompromised trials by phase

About Immunocompromised Clinical Trials

Looking for clinical trials for Immunocompromised? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Immunocompromised trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Immunocompromised clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 3

Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

COVID-19Lower Respiratory Tract InfectionImmunocompromised+1 more
Ansun Biopharma, Inc.274 enrolled67 locationsNCT03808922
Recruiting

Optimizing the Diagnosis of Pneumocystis in Immunocompromised Patients

PneumocystisImmunocompromised Patients
Assistance Publique - Hôpitaux de Paris240 enrolled4 locationsNCT06890078
Recruiting
Phase 2

COVID-19 Booster and IIV Schedule in Immunocompromised Hosts

COVID-19Inflammatory Bowel DiseaseRheumatoid Arthritis (RA)+5 more
McGill University Health Centre/Research Institute of the McGill University Health Centre660 enrolled3 locationsNCT06599658
Recruiting

Immunogenicity, Efficacy and Safety of Recombinant Herpes Zoster Vaccine in Frail Patients

Immunocompromised Patients
Fondazione IRCCS Policlinico San Matteo di Pavia300 enrolled1 locationNCT07321808
Recruiting
Phase 1

Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

Hematopoietic and Lymphoid Cell NeoplasmImmunocompromised
M.D. Anderson Cancer Center16 enrolled1 locationNCT03425526
Recruiting

Personalized Immunological Score for the Prediction of Severe Infectious Events in Immunocompromised Patients and Tailored Management (PERISCOPE)

InfectionsImmunocompromised PatientsTransplant Patients
Fondazione IRCCS Policlinico San Matteo di Pavia150 enrolled1 locationNCT07379554
Recruiting

Analysis of the Specificity and Persistence of Nasal Immune Responses to Respiratory Viral Antigens in Immunocompromised and Healthy Cohorts

Healthy SubjectsOncological PatientsImmunocompromised Patients+2 more
Fondazione IRCCS Policlinico San Matteo di Pavia40 enrolled1 locationNCT07295535
Recruiting
Phase 2

Third Party Viral Specific T-cells (VSTs)

Viral reactivationViral InfectionInfection in an Immunocompromised Host
Children's Hospital Medical Center, Cincinnati750 enrolled4 locationsNCT02532452
Recruiting

Clinical Study on Immunogenicity and Safety of Lyophilized Vero Cell-Derived Human Rabies Vaccine in Special Populations

Chronic DiseaseImmunocompromisedRabies Exposure
Liaoning Chengda Biotechnology CO., LTD180 enrolled1 locationNCT07120464